Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tvardi Therapeutics, Inc. - Common Stock (NQ:TVRD)

2.038 -0.062 (-2.94%)
Streaming Delayed Price Updated: 10:29 AM EDT, Aug 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tvardi Therapeutics, Inc. - Common Stock

News headline image
DarkHorse Begins to Take Shape: Sphere 3D (NASDAQ: ANY) Marks a Key Milestone in AI Infrastructure Leadership
Via AB Newswire
Topics Artificial Intelligence
News headline image
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
SHAREHOLDER INVESTOR REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
From Tvardi Therapeutics, Inc.
Via Business Wire
News headline image
Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update
From Tvardi Therapeutics, Inc.
Via Business Wire
News headline image
TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
TVRD SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Tvardi
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
From Tvardi Therapeutics, Inc.
Via Business Wire
News headline image
TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Rosen Law Firm Encourages Tvardi Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – TVRD
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis
From Tvardi Therapeutics, Inc.
Via Business Wire
News headline image
Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference
From Tvardi Therapeutics, Inc.
Via Business Wire
News headline image
Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update
From Tvardi Therapeutics, Inc.
Via Business Wire
News headline image
Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
From Tvardi Therapeutics, Inc.
Via Business Wire
News headline image
Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis
From Tvardi Therapeutics, Inc.
Via Business Wire
News headline image
Tvardi Therapeutics to Participate in Upcoming Investor Conferences
From Tvardi Therapeutics, Inc.
Via Business Wire
News headline image
Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update
From Tvardi Therapeutics, Inc.
Via Business Wire
News headline image
Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference
From Tvardi Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.